BRAF oncogenic mutants evade autoinhibition through a common mechanism
Science · 2025
DOI: 10.1126/science.adp2742 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, 2025. Verfasst von Hugo Lavoie und 18 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Research in Immunology and Cancer, Laboratory of Intracellular Signaling, Université de Montréal, Montréal, QC, Canada. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Uncontrolled activation of the rat sarcoma (RAS)–extracellular signal–regulated kinase (ERK) pathway drives tumor growth, often because of oncogenic BRAF mutations. BRAF regulation, involving monomeric autoinhibition and activation by dimerization, has been intensely scrutinized, but mechanisms enabling oncogenic mutants to evade regulation remain unclear. By using cryo–electron microscopy, we solved the three-dimensional structures of the three oncogenic BRAF mutant classes, including the common V600E variant. These mutations disrupted wild-type BRAF's autoinhibited state, mediated by interactions between the cysteine-rich domain and kinase domain, thereby shifting the kinase domain into a preactivated conformation. This structural change likely results from helix αC displacement. PLX8394, a BRAF inhibitor that stabilizes helix αC in an inactive conformation, restored the autoinhibited conformation of oncogenic BRAF, explaining the properties of this class of compounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Research in Immunology and Cancer, Laboratory of Intracellular Signaling, Université de Montréal, Montréal, QC, Canada.
- Université de Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248, IECB, Pessac, France.
- Cryo-EM Core Facility, NYU Langone Health, New York, NY, USA.
- Department of Biochemistry & Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
- Département de Chimie, Université de Montréal, Montréal, QC, Canada.
- Department of Cell Biology, NYU Langone Health, New York, NY, USA.
ORCID-Profile: Hugo Lavoie, Ting Jin, Driss Lajoie, Marion Decossas, Patrick Gendron, Bing Wang, Frantisek Filandr, Malha Sahmi, Chang Hwa Jo, Sandra Weber, Geneviève Arseneault, Doris A Schuetz, David C Schriemer, Anne Marinier, William J Rice, Pierre Maisonneuve, Marc Therrien
Förderung
- NCI NIH HHS
Zitieren
APA
Lavoie, H., Jin, T., Lajoie, D., Decossas, M., Gendron, P., Wang, B., Filandr, F., Sahmi, M., Hwa Jo, C., Weber, S., Arseneault, G., Tripathy, S., Beaulieu, P., Schuetz, D. A., Schriemer, D. C., Marinier, A., Rice, W. J., Maisonneuve, P., & Therrien, M. (2025). BRAF oncogenic mutants evade autoinhibition through a common mechanism. Science. https://doi.org/10.1126/science.adp2742
Vancouver
Lavoie H, Jin T, Lajoie D, Decossas M, Gendron P, Wang B, et al. BRAF oncogenic mutants evade autoinhibition through a common mechanism. Science. 2025. doi:10.1126/science.adp2742
BibTeX
@article{Lavoie2025,
author = {Lavoie, Hugo and Jin, Ting and Lajoie, Driss and Decossas, Marion and Gendron, Patrick and Wang, Bing and Filandr, Frantisek and Sahmi, Malha and Hwa Jo, Chang and Weber, Sandra and Arseneault, Geneviève and Tripathy, Sasmita and Beaulieu, Pierre and Schuetz, Doris A and Schriemer, David C and Marinier, Anne and Rice, William J and Maisonneuve, Pierre and Therrien, Marc},
title = {BRAF oncogenic mutants evade autoinhibition through a common mechanism},
journal = {Science},
year = {2025},
doi = {10.1126/science.adp2742}
}
EUVIMED